{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:07:44Z","timestamp":1782950864145,"version":"3.54.5"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.nmd.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T02:33:48Z","timestamp":1543804428000},"page":"127-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical spectrum of neuromuscular complications after immune checkpoint inhibition"],"prefix":"10.1016","volume":"29","author":[{"given":"Araya","family":"Puwanant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-943X","authenticated-orcid":false,"given":"David","family":"Lacomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a A.","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2018.11.012_bib0001","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2018.11.012_bib0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0007","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","article-title":"The epidemiology of myasthenia gravis in central and western Virginia","volume":"42","author":"Phillips","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2018.11.012_bib0008","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2018.11.012_bib0009","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.nmd.2018.11.012_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0012","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0013","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0014","first-page":"S108","article-title":"Autoimmune neuromuscular complications triggered by PD-1 inhibitors: balancing treatment efficacy and side effects","volume":"82","author":"Isfort","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0015","doi-asserted-by":"crossref","first-page":"e9262","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2018.11.012_bib0016","doi-asserted-by":"crossref","first-page":"e7350","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2018.11.012_bib0017","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/annonc\/mdw613","article-title":"Vasculitic neuropathy induced by pembrolizumab","volume":"28","author":"Aya","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0018","first-page":"e1702","article-title":"Myasthenia gravis induced by nivolumab: a case report","volume":"9","author":"Mehta","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.nmd.2018.11.012_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp-2017-316510","article-title":"Acute demyelinating polyneuropathy induced by nivolumab","volume":"89","author":"Fukumoto","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2018.11.012_bib0021","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mus.23830","article-title":"Multifocal radiculoneuropathy during ipilimumab treatment of melanoma","volume":"48","author":"Manousakis","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0022","article-title":"PD-1 Inhibitor-associated Myopathies: emerging Immune-mediated Myopathies","author":"Liewluck","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nmd.2018.11.012_bib0023","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0024","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/CJI.0000000000000178","article-title":"Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases","volume":"40","author":"Pushkarevskaya","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nmd.2018.11.012_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.nmd.2018.11.012_bib0026","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.nmd.2018.11.012_bib0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2017.05.036","article-title":"Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy","volume":"83","author":"Boisseau","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","author":"Fellner","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0029","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study","volume":"56","author":"Svensson","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2018.11.012_bib0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/jnnp-2012-304057","article-title":"Overlooked non-motor symptoms in myasthenia gravis","volume":"84","author":"Suzuki","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2018.11.012_bib0031","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2018.11.012_bib0032","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0033","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0034","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0035","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","author":"March","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.nmd.2018.11.012_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26070","article-title":"The neuromuscular complications of immune checkpoint inhibitor therapy","author":"Kolb","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0037","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0038","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.4049\/jimmunol.166.10.6430","article-title":"Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis","volume":"166","author":"Wang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0040","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2018.11.012_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-018-0318-x","article-title":"Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab","volume":"6","author":"Cafuir","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0042","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0043","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract Neurol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0044","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nmd.2018.11.012_bib0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2018.11.012_bib0046","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","article-title":"Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment","volume":"40","author":"Diamantopoulos","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nmd.2018.11.012_bib0047","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1017\/S0317167100007939","article-title":"Autoimmune inflammatory myopathy after treatment with ipilimumab","volume":"36","author":"Hunter","year":"2009","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nmd.2018.11.012_bib0048","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0049","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0050","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.nmd.2018.11.012_bib0051","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0052","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1093858","article-title":"A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis","volume":"2017","author":"Sakai","year":"2017","journal-title":"Case Rep Med"},{"key":"10.1016\/j.nmd.2018.11.012_bib0053","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 antibody-induced guillain-barre syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0054","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25212","article-title":"Benign form of myasthenia gravis after nivolumab treatment","volume":"54","author":"Sciacca","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0055","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1002\/mus.25672","article-title":"Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma","volume":"56","author":"Sepulveda","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0056","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2018.11.012_bib0057","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000070","article-title":"Peripheral neuropathy associated with ipilimumab: a report of 2 cases","volume":"38","author":"Thaipisuttikul","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.nmd.2018.11.012_bib0058","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0059","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.25055","article-title":"Myasthenia gravis exacerbation associated with pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0060","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0061","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.nmd.2018.11.012_bib0062","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.nmd.2018.11.012_bib0063","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12991","article-title":"Case of respiratory discomfort due to myositis after administration of nivolumab","volume":"42","author":"Yoshioka","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0064","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/mus.25663","article-title":"Facial diplegia after pembrolizumab treatment","volume":"56","author":"Yost","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.11.012_bib0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab \u2013 durvalumab treatment","volume":"5","author":"John","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nmd.2018.11.012_bib0066","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00408-015-9716-8","article-title":"Severe acute orthopnea: ipilimumab-induced bilateral phrenic nerve neuropathy","volume":"193","author":"Jinnur","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.nmd.2018.11.012_bib0067","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s10637-011-9787-1","article-title":"Severe meningo-radiculo-neuritis associated with ipilimumab","volume":"30","author":"Bompaire","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.nmd.2018.11.012_bib0068","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/01658107.2017.1291686","article-title":"A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer","volume":"41","author":"Carrera","year":"2017","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.nmd.2018.11.012_bib0069","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/kex346","article-title":"Pembrolizumab-associated inflammatory myopathy","volume":"57","author":"Gandiga","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2018.11.012_bib0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.nmd.2018.11.012_bib0071","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu","year":"2017","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2018.11.012_bib0072","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5692\/clinicalneurol.cn-000991","article-title":"A case of myasthenia gravis and myositis induced by nivolumab","volume":"57","author":"Konoeda","year":"2017","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nmd.2018.11.012_bib0073","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1200\/JCO.2013.49.7735","article-title":"Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab","volume":"33","author":"Luke","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nmd.2018.11.012_bib0074","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2018.11.012_bib0075","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618304875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618304875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:32Z","timestamp":1760774912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896618304875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0960896618304875"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2018.11.012","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}